The Food and Drug Administration (FDA) of the United States has now given the approval to the Omnipad 5 Automated Insulin Delivery System developed by the Insulet company for the patients of type 1 diabetes from the age of six years and above, and the new system has been claiming that the new system is going to be the first tubeless automated insulin deliver system.
The launch has come with a compatible with the integration of the smartphone and Dexcom G6 Continuous Glucose Monitor (CGM) System that is responsible for protecting the patients from the variations. Along with the SmartAdjust technology, the Omnipod 5 system has also been including a tubeless insulin Pod, Dexcom G6 CGM and the mobile app of Omnipod 5 along with the integrated calculators known as SmartBolus.
This new device has also been designed for the purpose of managing the glucose with the tubes, along with the fingersticks and also multiplying the daily number of the injections. Shacey Petrovic, chief executive officer and president and Insulet said that, the Omnipod 5 has been a life-changing technology, which the company is believing that, it is going to be revolutionizing the market along with the lives of the people suffering with the type 1 diabetes.
He also said that, they are very proud of this new and simple system, which has been designed for the purpose of delivering the freedom and for also simplifying the management of Insulin along with improving the control of glucose for the users of the company.